Document is current
Any future updates will be listed below
-
Authors
Crist, Richard C.
Chehimi, Samar N. https://orcid.org/0000-0002-0701-9260
Divakaran, Saurabh S. https://orcid.org/0000-0002-7530-045X
Montague, Michael J. https://orcid.org/0000-0003-0253-4404
Tremblay, Sébastien
Snyder-Mackler, Noah https://orcid.org/0000-0003-3026-6160
Bohlen, Martin O.
Chiou, Kenneth L.
Zintel, Trish M.
,
Brent, Lauren J. N.
Higham, James P.
Martinez, Melween I.
Platt, Michael L. https://orcid.org/0000-0003-3912-8821
Juul, Halvor
Silvestri, Guido
Hayes, Matthew R.
Kolson, Dennis L.
Reiner, Benjamin C. https://orcid.org/0000-0001-7796-587X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P30MH097488)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (P30AI045008)
Penn Mental Health AIDS Research Center (PMHARC) Penn Center for AIDS Research
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK115762)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS122570)
- License Information
-
More Information
Article History
Received: 15 October 2023
Revised: 17 December 2024
Accepted: 27 January 2025
First Online: 31 January 2025
Competing interests
: BCR and MRH receive research funding from Novo Nordisk and Boehringer Ingelheim that was not used in support of these studies. BCR receives in-kind support from Oxford Nanopore Technologies and 10x Genomics were not used in support of these studies. MRH receives research funding from Eli Lilly & Co., Gila Therapeutics, and Pfizer that was not used in support of these studies. MRH is CEO of Cantius Therapeutics, LLC which pursues biological work unrelated to the current study. All other authors declare no competing interests.
